2022
Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia?
Shallis RM, Bewersdorf JP, Stahl MF, Halene S, Zeidan AM. Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia? Cancers 2022, 14: 2434. PMID: 35626039, PMCID: PMC9140008, DOI: 10.3390/cancers14102434.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAcute myeloid leukemiaMyeloid leukemiaAllogeneic hematopoietic stem cell transplantationHematopoietic stem cell transplantationCD47/SIRPαIntensive induction therapyAvailable therapeutic optionsStem cell transplantationStandard of careAvailable clinical dataTesting of agentsInduction therapyMedian overallRefractory settingAggressive treatmentTim-3Immune checkpointsPreclinical rationaleTherapeutic optionsCell transplantationEfficacy dataClinical dataPatientsMolecular subgroupsTherapeutic agents
2021
Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options
Lewis R, Bewersdorf JP, Zeidan AM. Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options. Cancer Management And Research 2021, 13: 645-657. PMID: 33531837, PMCID: PMC7846829, DOI: 10.2147/cmar.s240600.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsLower-risk myelodysplastic syndromesErythropoiesis-stimulating agentsTherapeutic optionsSymptomatic anemiaMyelodysplastic syndromeRed blood cell transfusionFurther therapeutic optionsBlood cell transfusionAvailable therapeutic optionsMajority of patientsManagement of anemiaPrimary clinical goalQuality of lifeResultant cytopeniasCell transfusionFrequent transfusionsImmunosuppressive therapyClinical improvementMost patientsSelect patientsTransfusion burdenClinical managementIron overloadNovel agentsAdditional therapeutics